Articles related to SGLT2 INHIBITORS

Recent research comparing SGLT2 inhibitors and dulaglutide in older patients with type 2 diabetes suggests a potential difference in dementia risk. The study estimated a risk ratio of 0.81 (CI, 0.56 to 1.16) for SGLT2 inhibitors compared to dulaglutide.

In patients with type 2 diabetes and stage 5 chronic kidney disease, the use of SGLT2 inhibitors is associated with a lower risk of initiating dialysis and experiencing major cardiovascular events, providing a promising therapeutic avenue in a population at elevated risk.

SGLT-2 inhibitors have emerged as a cornerstone in managing HFrEF and CKD, demonstrating substantial reductions in cardiovascular and renal adverse outcomes. This class of medications is reshaping the therapeutic approach in patients with these comorbid conditions, providing a dual benefit that was once considered challenging to achieve.

The approval of empagliflozin opens up a new avenue in CKD treatment. With its proven efficacy in reducing the risk of disease progression by 28%, it offers a promising alternative for healthcare professionals dealing with this prevalent condition.

Explore the study’s analysis, which also uncovers potential cardiovascular benefits associated with SGLT2i initiation among patients with gout and type 2 diabetes.

Brenzavvy, the latest addition to the diabetes treatment landscape, promises a cost-effective approach to managing type 2 diabetes. Discover how this newly approved drug could redefine the treatment paradigm for patients.